All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

13

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 13 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Gvoke Hypopen 2-Pack

Glucagon

D$48.3M+27%51,029$947$1,699.14
Baqsimi

Glucagon

D$21.5M-16%31,463$683$282.93
Glucagon Emergency Kit

Glucagon

D$19.0M+3%44,158$429$228.97
Gvoke Hypopen 1-Pack

Glucagon

D$13.4M+35%21,021$635$1,564.63
Glucagen*

Glucagon* · J1610

B$4.8M-18%21,431$222$186.83
Glucagen

Glucagon

D$3.5M-28%6,698$526$315.61
Gvoke PFS 1-Pack Syringe

Glucagon

D$3.0M-5%4,601$641$1,568.88
Glucagon Emergency Kit*

Glucagon HCL* · J1611

B$2.3M+79%17,015$138$120.43
Glucagon Emergency Kit

Glucagon HCl

D$1.6M+33%3,006$540$288.54
Gvoke PFS 2-Pack Syringe

Glucagon

D$1.6M-5%1,622$982$1,531.07
Gvoke

Glucagon

D$964K+54%1,557$619$1,525.13
Zegalogue Autoinjector

Dasiglucagon HCl

D$184K+585%226$813$494.77
Zegalogue Syringe

Dasiglucagon HCl

D$8Kn/a12$698$498.55

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.